Ilofotase alfa

Protein / enzyme

AAM-Pharma

Ilofotase alfa is one of 10 small molecule programs targeting Hypophosphatasia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypophosphatasiaActive, not recruiting

HypophosphatasiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hypophosphatasia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Rituxan

Roche

Approved

1 3

Folvite

Eli Lilly

Approved

1 4

Fosrenol

Takeda

Approved

—5

Velcade

SShilpa Grover, MD, MPH

Approved

1 6

Ivig

Argenx

Approved

1 7

STRENSIQ

AstraZeneca

Phase 2

14 8

ALXN1850

AstraZeneca

Phase 3

2 9

BPS804

Ultragenyx

Phase 2

1 10

Ilofotase alfa

AAM-Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypophosphatasia1 trial

Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia

Completed·AAM-Pharma·Phase 1/2·NCT05890794·12 enrolled

After Cardiac Surgery1 trial

Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

Completed·AAM-Pharma·Phase 2·NCT06168799·271 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ilofotase alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ilofotase alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ilofotase alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AM-Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Company: AAM-Pharma

Ilofotase alfa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypophosphatasia1 trial

After Cardiac Surgery1 trial

References

Drug Info

Quick Facts

Related News